{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+transplant", "query": { "intervention": "Allogeneic transplant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1584, "total_pages": 159, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+transplant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T17:11:58.334Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00074269", "title": "Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 5, "start_date": "2003-07", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-09-05T17:11:58.334Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074269" }, { "nct_id": "NCT03719105", "title": "Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "NK-Cell Lymphoma", "NK-Cell Leukemia", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "pralatraxate,", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "calaspargase pegol", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "31 Years", "sex": "ALL", "summary": "1 Year to 31 Years" }, "enrollment_count": 40, "start_date": "2019-03-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-05T17:11:58.334Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719105" }, { "nct_id": "NCT00964821", "title": "Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Nonmalignant Neoplasm" ], "interventions": [ { "name": "trivalent influenza vaccine", "type": "BIOLOGICAL" }, { "name": "Immunoenzyme technique", "type": "OTHER" }, { "name": "Laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 459, "start_date": "2007-01", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2017-11-07", "last_synced_at": "2026-09-05T17:11:58.334Z", "location_count": 2, "location_summary": "Duarte, California • Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00964821" }, { "nct_id": "NCT00888316", "title": "Iron Overload in Patients Undergoing Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Hematopoietic Stem Cell Transplantation", "Allogeneic Hematopoietic Cell Transplantation" ], "interventions": [ { "name": "magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "Serum ferritin", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 112, "start_date": "2008-12", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-09-05T17:11:58.334Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00888316" }, { "nct_id": "NCT00160355", "title": "Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Wiskott-Aldrich Syndrome" ], "interventions": [ { "name": "Hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "Miltenyi CliniMACS selection system", "type": "DEVICE" }, { "name": "Fludarabine, Melphalan, Thiotepa", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DEVICE", "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "MALE", "summary": "Up to 18 Years · Male only" }, "enrollment_count": 4, "start_date": "2005-05", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2017-04-26", "last_synced_at": "2026-09-05T17:11:58.334Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00160355" }, { "nct_id": "NCT05350163", "title": "T-cell Receptor α/β Depleted Donor Lymphocyte Infusion", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoid Leukemia, Acute", "Myeloid Malignancy", "Plasma Cell Tumor" ], "interventions": [ { "name": "T-cell Receptor α/β Depleted Donor Lymphocyte Infusions", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Guenther Koehne", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 11, "start_date": "2022-04-05", "completion_date": "2023-09-18", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-09-05T17:11:58.334Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05350163" }, { "nct_id": "NCT01998633", "title": "Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemophagocytic Lymphohistiocytosis", "Chronic Active Epstein-Barr Virus Infection", "Chronic Granulomatous Disease", "HIGM-1", "Leukocyte Adhesion Deficiency", "IPEX" ], "interventions": [ { "name": "Hematopoietic Stem Cell Transplant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Months", "maximum_age": "45 Years", "sex": "ALL", "summary": "4 Months to 45 Years" }, "enrollment_count": 47, "start_date": "2013-12", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2022-12-08", "last_synced_at": "2026-09-05T17:11:58.334Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998633" }, { "nct_id": "NCT05463133", "title": "Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Granulomatous Disease" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Pheripheral blood stem cells", "type": "BIOLOGICAL" }, { "name": "Emapalumab-Izsg", "type": "DRUG" }, { "name": "Tociluzumab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "4 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2022-07-08", "completion_date": "2032-12-31", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-05T17:11:58.334Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05463133" }, { "nct_id": "NCT03314974", "title": "Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Lymphoma", "Chronic Myelogenous Leukemia", "Plasma Cell Leukemia", "Myeloproliferative Neoplasms", "Myelofibrosis", "Myelodysplasia", "Refractory Anemia", "High Risk Anemia", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone B-Cell Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle-Cell Lymphoma", "Prolymphocytic Leukemia", "Diffuse Large Cell Non Hodgkins Lymphoma", "Lymphoblastic Lymphoma", "Burkitt Lymphoma", "High Grade Non-Hodgkin's Lymphoma, Adult", "Multiple Myeloma", "Juvenile Myelomonocytic Leukemia", "Biphenotypic/Undifferentiated/Prolymphocytic Leukemias", "MRD Positive Leukemia", "Natural Killer Cell Malignancies", "Acquired Bone Marrow Failure Syndromes" ], "interventions": [ { "name": "HSCT with TBI Regimen", "type": "BIOLOGICAL" }, { "name": "HSCT with Non-TBI Regimen", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "ALL", "summary": "Up to 60 Years" }, "enrollment_count": 300, "start_date": "2018-03-30", "completion_date": "2028-06-10", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-09-05T17:11:58.334Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03314974" }, { "nct_id": "NCT00803010", "title": "Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Graft Versus Host Disease" ], "interventions": [ { "name": "Tacrolimus (TAC)", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Rapamycin (RAPA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 74, "start_date": "2008-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2015-07-31", "last_synced_at": "2026-09-05T17:11:58.334Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00803010" } ] }